This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by McCown, M. F.
Right arrow Articles by Nájera, I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by McCown, M. F.
Right arrow Articles by Nájera, I.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, May 2009, p. 2129-2132, Vol. 53, No. 5
0066-4804/09/$08.00+0     doi:10.1128/AAC.01598-08
Copyright © 2009, American Society for Microbiology. All Rights Reserved.

GT-1a or GT-1b Subtype-Specific Resistance Profiles for Hepatitis C Virus Inhibitors Telaprevir and HCV-796{triangledown}

Matthew F. McCown, Sonal Rajyaguru, Simran Kular, Nick Cammack, and Isabel Nájera*

Roche Palo Alto LLC, 3431 Hillview Ave., Palo Alto, California 94304

Received 2 December 2008/ Returned for modification 16 January 2009/ Accepted 25 February 2009

In vitro, telaprevir selects subtype-specific resistance pathways for hepatitis C virus GT-1a and GT-1b, as described to have occurred in patients. In GT-1a, the HCV-796 resistance mutation C316Y has low replication capacity (7%) that can be compensated for by the emergence of the mutation L392F or M414T, resulting in an increase in replication levels of ≥10-fold.

* Corresponding author. Mailing address: Department of HCV Drug Discovery and Resistance Monitoring, Virology DBA, Roche Palo Alto LLC, 3431 Hillview Ave., Palo Alto, CA 94304. Phone: (650) 855-5134. Fax: (650) 354-7554. E-mail: isabel.najera{at}roche.com

{triangledown} Published ahead of print on 9 March 2009.

Antimicrobial Agents and Chemotherapy, May 2009, p. 2129-2132, Vol. 53, No. 5
0066-4804/09/$08.00+0     doi:10.1128/AAC.01598-08
Copyright © 2009, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Kieffer, T. L., Kwong, A. D., Picchio, G. R. (2009). Viral resistance to specifically targeted antiviral therapies for hepatitis C (STAT-Cs). J Antimicrob Chemother 0: dkp388v1-dkp388 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»